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Abstract 
Background 
Mucopolysaccharidosis type-III (MPS III) is an autosomal recessive lysosomal storage 
disorder. It causes progressive physical and cognitive decline and has been linked to 
increased incidences of behavioural problems. 
Methods 
Data on the behaviour and adaptive skills of 20 children with MPS III and 25 children with 
intellectual disability (ID) (17 included in analysis) were gathered via parental report 
questionnaire. The frequencies of different types of behaviour displayed by children with 
MPS III and children with ID were compared across two age categories. 
Results 
The total frequency of challenging behaviours displayed by children aged 2–9 years with 
MPS III and ID was not significantly different. Behaviours associated with hyperactivity, 
orality, unusual body movements and inattention were seen significantly more frequently in 
2–9 year olds with MPS III than in those with ID. Children aged 10–15 years with MPS III 
showed significantly fewer problem behaviours than a contrasting group with ID. The 
frequency of challenging behaviours displayed by children with MPS III and their adaptive 
skills was found to decrease with age. 
Conclusions 
Behaviours relating to hyperactivity, orality, unusual body movements and inattention are 
part of the behavioural phenotype of the middle phase of MPS III. The late phase of MPS III 
is associated with low rates of problem behaviour and loss of adaptive skills. Therefore, 
families with a child with MPS III may benefit from a different type of clinical service when 
the child is aged 2–9 years, than when aged 10–15 years. 
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Background 
Mucopolysaccharidosis type-III (MPS III (Sanfilippo syndrome)) is a recessively inherited 
lysosomal storage disorder and is the most prevalent of the seven mucopolysaccharide (MPS) 
disorders, occurring 0.28–4.1 in 100,000 live births [1]. MPS disorders are caused by 
deficiency in enzymes responsible for the degradation of glycosaminoglycans (GAGs) and 
subsequent GAG accumulation in various organs causes a multi-system disease [2]. MPS III 
has four subtypes A to D associated with a specific enzyme deficiency. All four enzymes, 
heparan N-sulfatase, a-N-actylglucosaminidase, acetyl-CoA: a-glycosaminide and N-
acetylglucosamine 6-sulfatase (A to D, respectively), are associated with the breakdown of 
heparan sulphate [3]. The most prevalent type in the UK is type A; type B is less common 
and types C and D rare [4]. 
MPS III causes severe neurological impairment and a gradual decline in functioning with a 
tri-phasic clinical course. The beginning phase (1–2 years) is characterised by developmental 
delay but normal stature and physical growth [5]. The middle phase (2–9 years) shows 
considerable variation and is characterised by behavioural problems and sleep disturbance. 
The late phase (10+ years) is associated with skill loss, reduced behaviour problems, loss of 
motor skills, increased spasticity, seizures and swallowing difficulties [5]. Other symptoms 
include recurrent diarrhoea; ear, nose and throat infections; and visual impairment [6]. Age of 
death varies within and between subtypes with a median of 15.2 years for type A [7] and 34 
years for type C [8]. 
A recent survey of care professionals and families investigating non-carcinomatous life-
limiting conditions identified MPS disorders as the primary priority for further research, 
given the complex symptom profile, difficulties in managing symptoms and distress 
experienced by families [9,10]. Research into treatments is ongoing but inconclusive [11]. 
A recent systematic review of behaviour and development in MPS III [12] identified 
behaviour problems, including restlessness and hyperactivity, physical aggression, unusual 
affect (laughing/screaming/crying), ‘tantrums’ and orality [5,7,8,13-20], as strongly 
associated with the middle phase, thence declining with age and loss of functions [8]. Sleep 
and circadian rhythm were found to be significantly different from matched controls in two 
studies [5,21]. Linguistic and motor development was ‘relatively normal’ for the 1st year 
with first signs and symptoms differing between subtypes, ranging from 2 years 3 months to 
5 years. Age at onset of cognitive delay and rate of decline increased across types A to D 
respectively [13]. 
Research to date has been limited by inadequate measurement, control groups, statistical 
analyses and methodologies (e.g. case-note review). To address this, the present study used 
validated and syndrome-specific measures and a genetically distinct, ability-matched, control 
group to address the following research questions: 
1: Do the frequencies of challenging behaviour differ significantly between children with 
MPS III and children with ID? 
2: Are any types of challenging or adaptive behaviour observed significantly more frequently 
in children with MPS III than in children with ID? 
Methods 
Recruitment 
Children with MPS III 
This study was conducted alongside other studies investigating sleep, circadian rhythm and 
family functioning [22,23] with recruitment through the MPS Society UK and a genetics 
department in the North West of England. Questionnaires were sent to 25 families with a 
child with MPS III with 20 returned. 
Children with intellectual disability (ID) 
Families of children with intellectual disability (ID) were recruited through national and local 
MENCAP and 30 local parent support agencies across the UK. Sixty-six questionnaire packs 
were sent out with 24 returned. 
Sample 
Children with MPS III were included in the study if they had a diagnosis of MPS III (any 
subtype) made via genetic/enzyme testing, were resident in the UK and their parents 
understood written English. People with MPS III were excluded if they had received gene or 
enzyme replacement therapy or a bone marrow transplant and if they were under 2 years of 
age. Children with ID were included if they had an intellectual disability, were aged 2–15 
years, their parents understood written English and were resident in the UK and were 
excluded if they had an autistic spectrum condition but an IQ > 70 and if they were under 2 
years of age. 
Design 
Parents/carers (MPS III or ID) ‘opted in’ via telephone or email. Information and consent 
forms and questionnaires were sent via post. When possible, families were telephoned to 
collect missing data. 
Materials/measures 
Demographic Questionnaire—used to collection information on age, diagnosis, treatments 
received, deafness, blindness, epilepsy, medications and GP details. 
Learning Disability Casemix Scale (LDCS) [24]—measures degree (mild/moderate/severe) 
of ID (A) and frequency and severity of challenging behaviour (C), based upon the widely 
used Wessex Behaviour Schedule [25]. 
Vineland Adaptive Behavior Scale, Second Edition-Parent/Carer Rating Form (VABS-II) 
[26]—measures current adaptive and maladaptive behaviour across 11 subdomains within 4 
domains of communication, daily living skills, socialisation and motor skills. Each subdomain 
contains lists of adaptive skills and respondents rate if the child/adult can do this; ‘Usually’ = 
2, ‘Sometimes/Partially’ = 1 or ‘Never’ = 0. The measure gives an overall adaptive behaviour 
score (Adaptive Behaviour Composite) as well as age equivalent scores and standard scores 
for each domain. Internal consistency reliability is moderate to high for domain scores (a = 
0.71–0.95) and high for Adaptive Behaviour Composite score (a = 0.86–0.98) across all ages 
[26]. 
Aberrant Behaviour Checklist (ABC) [27]—measures severity of a child’s behaviour in the 
last month, with each behaviour problem rated from 0 (not a problem at all) to 3 (the problem 
is severe in degree) across domains of irritability/agitation, crying/lethargy, social 
withdrawal/stereotypic behaviour, hyperactivity/noncompliance and inappropriate speech. 
Internal consistency is good across all domains (a = 0.86–0.95) [27-29]. 
Eyberg Child Behaviour Inventory (ECBI) [30,31]—measures frequency and severity of 
current behavioural problems for children aged 2–17 years, with frequency of behaviours 
rated from 1 (never) to 7 (always) to give a behaviour ‘intensity’ score. Respondents state if 
each behaviour is a problem for them, and the number of problematic behaviours is summed 
to give a ‘problem’ score. The ECBI has high internal consistency for both problem (a = 
0.94) and intensity (a = 0.95) domains [32]. It has been found to provide a homogenous 
measure of conduct problems when used via post [32]. 
Sanfilippo Behaviour Rating Scale (SBRS) [33]—comprises three sections: communication, 
tantrums and behaviour. The scale is composed of past and present communication skills 
(Section I); frequency, duration and emotions expressed during tantrums (Section II); and 
frequency, onset and cessation of relevant motor, perceptual, social and emotional skills and 
behaviour (Section III). The SBRS is under development for use in MPS III treatment trials. 
Statistical analysis 
All data were anonymised, stored and analysed in accordance with the Data Protection Act 
(1998). Data were analysed using the Statistical Package for the Social Sciences (SPSS) 
versions 16.0 and 19.0. Children were divided into age groups associated with stages of the 
disorder: 2–9 years (middle phase) and 10–15 years (late phase), with poorly matched 
controls being excluded from the ID group. 
Questionnaire scores were tested for normality using the Kolmogorov-Smirnov test and by 
examination of Q-Q and P-P probability plots (graphical representation and comparison of 
the data distribution). Although most scores were normally distributed, the sample size was 
small, and non-parametric statistics (Mann-Whitney U and Spearman rho) were used for all 
analyses with two-tailed significance values. As the SBRS is a relatively new measure, 
Cronbach’s α was calculated to test for reliability (internal consistency). 
Total measure scores and domain scores were calculated according to the measure guidelines. 
The functioning of children with MPS III and ID was so low that the standardised scores and 
some age-equivalent scores on the VABS-II were not meaningful, and raw scores were 
therefore used for comparison as the groups were matched for age and ability. Raw scores 
were summed to give domain raw scores, and these were summed to give a measure raw 
score. All measure scores, domain scores and subdomain scores were compared between 
children with MPS III and children with ID. Bonferroni adjustments were not used as these 
would have given too conservative a cut-off for significance, increasing the chance of Type II 
errors [34]. Effect sizes (r = Z/√n [35]) were computed for all significant findings taking p < 
0.05 used as cut-off for significance in all comparisons. 
Ethical approval 
This study was approved by NHS North West Research Ethics Committee, University of 
Manchester School of Psychological Sciences Ethics Committee and Central Manchester 
Foundation Trust Research and Design department. 
Results 
Data for 20 children with MPS III (N = 10 aged 2–9 years; N = 10 aged 10–15 years) and 25 
children with ID (N = 15 aged 2–9 years; N = 10 aged 10–15 years) were collected. In the 2–
9-year age group, all children with MPS III had severe ID, and therefore, only children 
receiving a score indicative of severe ID were included in the control group (N = 10 
remained). In the 10–15-year age group, all the children with MPS III had severe or moderate 
ID and children with mild ID were excluded from the comparison group (N = 7) (Table 1). 
  
Table 1 Participant demographics 
  2–9-year age group 10–15-year age group 16+ year age group 
MPS III N 10 10 5 
Median age 4.5 12.5 28 
Youngest to oldest 2–9 10–15 16–32 
Median ID score 30 (N = 8) 37.5 39 
(range) (26–36) (20–40) (31–41) 
Gender 7 male, 3 female 4 male, 6 female 2 male, 3 female 
Genetic subtypes 2xA, 7xB, C 7xA, 3xB 2xA, 2xB, C 
ID N 10 7 - 
Median age 4 12  
Youngest to oldest 2–8 10–15  
Median ID score 31.5 22  
(range) (26–38) (17–32)  
Diagnosis 2xASD, 3xDS, AS, CD 3xASD, AS, CD  
Gender 7 male, 3 female 4 male, 3 female  
ASD autism spectrum disorder, DS Down syndrome, AS Angelman syndrome, CD chromosome deletion 
[unspecified]. 
The SBRS current understanding, past understanding, orality, body movements, fearfulness, 
attention, self-control/compliance and mood, anger and aggression domains had good 
internal reliability (α > 0.7), the remaining domains having poor internal reliability (α < 0.7). 
As seen in Figure 1, there was an outlier in the MPS III group with a high level of skills aged 
11 years. Subsequent analyses were conducted both with and without this outlier, but the 
latter are only reported if these differed from those conducted with the whole dataset. Skills 
increased with age for the ID group (green line) but decreased with age for the MPS III group 
(blue line), with LDCS A score being significantly correlated with age in the MPS III group 
(r = 0.728, p = 0.01). 
Figure 1 Graph showing the relationship between age and disability score. 
Frequency of challenging behaviour (ECBI Intensity score) and level of disability (LDCS A 
score) were negatively correlated in both the MPS III (r = −0.676, p = 0.008) and ID (r = 
−0.573, p = 0.02) groups, but this relationship was non-significant in the MPS III when the 
outlying case was omitted, which was most likely due to the lack of variability in the MPS 
group. 
Figure 2 shows the relationship between the ECBI behaviour intensity score and age. For the 
MPS III group (blue line), the frequency of behavioural problems reduced with age, while for 
the ID group (green line) the frequency increases. Age and intensity score were significantly 
negatively correlated for children with MPS III (r = −0.639, p = 0.008), but this was non-
significant when the outlier was removed. 
Figure 2 Graph of the relationship between ECBI Intensity score and age. 
Middle phase (2–9-year-old group) 
In terms of adaptive skills measured by the VABS-II, MPS III group scores were 
significantly higher than ID scores for the gross motor skills subdomain only, with a large 
effect size (U = 13, z = −2.493, r = −0.605, p = 0.013) (Tables 2 and 3). 
Table 2 VABS-II subdomain scores (2–9 year olds) 
Domain Subdomain MPS III raw score 
median (N, range) 
MPS III age equivalent 
(years:months) 
ID raw score median 
(N, range) 
ID age equivalent 
(years:months) 
p value 
Communication Receptive 11 (9, 5–16) 1:0 12.5 (10, 6–23) 1:1 0.512 
Expressive 17 (9, 9–42) 0:10 13 (10, 8–22) 0:8 0.164 
Written 0 (8, 0–3) ≤1:10 0 (9, 0–14) ≤1:10 0.301 
Daily living skills Personal 15 (9, 7–26) 1:5 12 (10, 4–34) 1:2 0.870 
Domestic 1 (9, 0–10) 0:10 0 (10, 0–8) ≤0:7 0.435 
Community 3 (9, 0–7) 0:11 3 (10, 0–8) 0:11 0.901 
Socialisation Interpersonal relationships 23 (8, 15–36) 0:9 22.5 (10, 14–43) 0:8 0.447 
Play and leisure 13.5 (8, 0–26) 1:2 6 (9, 3–22) 0:7 0.311 
Coping skills 5 (9, 0–18) 1:1 5.5 (0, 0–13) 1:1 0.967 
Motor skills Gross 59 (7, 46–62) 2:5 42 (10, 12–58) 1:4 0.013 
Fine 30 (7, 14–37) 2:8 23 (9, 9–28) 2:0 0.050 
Table 3 Behaviour-related domain scores (2–9 age group) 
Measure/domain MPS III ID p value 
 Median (N, range) Median (N, range)  
ECBI    
    Intensity score 128 (8, 63–180) 115 (9, 57–154) 0.336 
    Problem score 16 (7, 0–27) 11 (9, 1–20) 0.761 
ABC    
    Irritability 8 (7, 3–31) 11.5 (10, 1–22) 0.494 
    Lethargy 10 (7, 0–29) 9.5 (10, 1–29) 0.732 
    Stereotypy 4 (7, 0–12) 0.5 (10, 0–14) 0.577 
    Hyperactivity 27 (7, 10–38) 11 (10, 5–28) 0.031 
    Inappropriate speech 3 (7, 0–9) 0 (10, 0–5) 0.08 
    ABC total score 58 (7, 13–113) 34 (10, 10–91) 0.525 
SBRS    
    Current understanding 28 (9, 11–35) 24.5 (10, 5–40) 0.902 
    Past understanding 30 (7, 24–41) 12.5 (4, 0–35) 0.130 
    Current expression 8 (9, 1–12) 6.5 (10, 4–14) 0.967 
    Past expression 6 (6, 2–17) 3 (5, 0–6) 0.125 
    Orality 29 (9, 11–33) 12.5 (10, 0–24) 0.005 
    Body movements 22 (9, 5–27) 6.5 (10, 0–18) 0.013 
    Interactions with objects 14 (9, 2–20) 7 (10, 0–12) 0.022 
    Activity and routines 22 (9, 11–36) 15.5 (10, 8–26) 0.078 
    Emotional function 5 (9, 0–16) 4 (10, 0–12) 0.536 
    Safety consciousness 14 (9, 8–18) 10.5 (10, 6–18) 0.267 
    Fearfulness 28 (9, 16–38) 28 (10, 9–40) 0.806 
    Social interaction 16 (9, 8–24) 20 (10, 12–26) 0.388 
    Eye contact 8 (9, 2–18) 5 (10, 0–10) 0.201 
    Emotional engagement 7 (9, 0–13) 11.5 (10, 1–16) 0.234 
    Comfort seeking 9 (9, 6–23) 5.5 (10, 0–24) 0.078 
    Attention 14 (9, 10–18) 8.5 (10, 5–18) 0.040 
    Self-control/compliance 11 (9, 0–18) 9.5 (10, 2–15) 0.461 
    Mood, anger and aggression 11 (9, 5–33) 10 (10, 4–24) 0.582 
    Self-gratification 0 (9, 0–7) 0.5 (10, 0–11) 0.649 
In the MPS III group, the median ECB score in the MPS III group exceeded clinical cut-off 
(15); ABC hyperactivity scores were significantly higher with a large effect size (U = 13, z = 
−2.151, r = −0.522, p = 0.031), and SBRS domain scores were significantly higher for orality 
(U = 11, z = −2.78, r = −0.638, p = 0.005), body movements (U = 14.5, z = −2.493, r = 
−0.572, p = 0.013), interactions with objects (U = 14.5, z = −2.493, r = −0.572 p = 0.022) 
and attention (U = 20, z = −2.054, r = −0.471 p = 0.04) domains. Of the children with MPS 
III, 67% reported some sleep problems and 33% reported severely disrupted sleep. 
Late phase (10–15 years group) 
Total VABS-II measure and domain scores were lower in the MPS III group with daily living 
skills being significantly so (U = 8.5, z = −2.261, r = − 0.584, p = 0.024) (Table 4). 
Significantly lower scores with large effect sizes were reported for written communication (U 
= 11, z = −2.042, r = −0.527, p = 0.041), personal skills (U = 9.5, z = −2.143, r = −0.553, p = 
0.032), domestic skills (U = 3, z = −3.05, r = −0.788, p = 0.002), community skills (U = 8.5, z 
= −2.288, r = −0.591, p = 0.022) and coping skills (U = 9.5, z = −2.16, r = −0.558, p = 0.031) 
subdomains. When the outlier in the MPS III group was removed, significantly lower scores 
were reported for both gross motor skills (p = 0.018) and fine motor skills (p = 0.030). All 
age-equivalent scores for children with MPS III fell below 18 months. 
Table 4 VABS Subdomain scores (10–15 year olds) 
Domain Subdomain Median MPS III 
score 
median (N, range) 
MPS III age equivalent 
(years:months) 
Median ID score 
median 
(N, range) 
ID age equivalent 
(years:months) 
p value 
Communication Receptive 10.5 (8, 3–33) 0:11 21 (7, 8–28) 1:9 0.223 
Expressive 16 (8, 2–90) 0:9 61 (7, 9–73) 2:10 0.165 
Written 0 (8, 0–21) ≤1:10 10 (7, 0–41) 4:6 0.041 
Daily living 
skills 
Personal 11 (8, 0–58) 1:1 40 (7, 14–52) 2:11 0.032 
Domestic 0 (8, 0–8) ≤0:7 13 (7, 1–22) 4:11 0.002 
Community 1 (8, 0–24) 0:3 22 (7, 3–23) 4:10 0.022 
Socialisation Interpersonal 
relationships 
23 (8, 11–47) 0:9 23 (7, 8–42) 0:9 0.449 
Play and leisure 12 (8, 2–32) 1:1 14 (6, 8–36) 1:3 0.172 
Coping skills 3.5 (8, 0–29) 0:7 10 (7, 6–17) 2:1 0.031 
Motor skills Gross 12 (7, 3–79) 0:7 47 (7, 4–67) 1:8 0.096 
Fine 16.5 (8, 1–54) 1:3 34 (7, 12–64) 3:0 0.093 
ECBI behaviour intensity and problem scores were significantly lower for children with MPS 
III than ID (Table 5), with large effect sizes, (U = 9, z = −2.199, r = −0.568, p = 0.028) and 
(U = 6.5, z = −2.086, r = −0.578, p = 0.037), respectively. The behaviour intensity score for 
children with ID exceeded clinical threshold (131) for problem behaviour while the MPS III 
score does not. The MPS III group had significantly lower scores on the irritability domain 
(U = 12.5, z = −2.025, r = −0.506, p = 0.043) and on the current understanding (U = 11, z = 
−2.345, r = −0.569, p = 0.019) and current expression subdomains (U = 6, z = −2.848, r = 
−0.691, p = 0.004) of the SBRS. Of the MPS III group, 90% were reported to have shown 
better comprehension and expressive communication skills in the past, compared to 28.5% of 
the ID group. Of the children with MPS III, 60% had sleep problems (40% severely 
disrupted), 90% were no longer continent, 10% had behavioural problems or over-activity, 
50% no longer walked and 60% were unresponsive most of the time. 
Table 5 Behaviour-related domain scores (10–15 year olds) 
 MPS III 
median (N, range) 
ID median 
(N, range) 
p value 
ECBI    
    Intensity score 76 (8, 36–174) 155 (7, 74–201) 0.028 
    Problem score 1 (7, 0–21) 14.5 (6, 1–29) 0.037 
ABC    
    Irritability 2 (9, 0–24) 23 (7, 1–40) 0.043 
    Lethargy 7 (9, 2–28) 7 (7, 4–27) 0.915 
    Stereotypy 2 (9, 0–14) 5 (7, 8) 0.183 
    Hyperactivity 7 (9, 2–28) 23 (7, 1–41) 0.152 
    Inappropriate speech 0 (9,0- 5) 4 (7, 0–12) 0.054 
    ABC total score 26 (9, 6–80) 54 (7, 11–106) 0.081 
SBRS    
    Current understanding 10 (10, 2–38) 33 (7, 14–41) 0.019 
    Past understanding 28 (9, 16–42) 42 (2, 4–20) 0.056 
    Current expression 2 (10, 0–12) 11 (7, 5–23) 0.004 
    Past expression 12 (9, 6–24) 12 (2, 4–20) 0.813 
    Orality 20 (10, 2–36) 15 (7, 0–26) 0.243 
    Body movements 10 (10, 4–30) 10 (7, 0–23) 0.590 
    Interactions with objects 11 (10, 3–19) 8 (7, 0–15) 0.240 
    Activity and routines 14 (10, 4–30) 20 (7, 6–26) 0.845 
    Emotional function 6 (10, 0–13) 5 (7, 2–14) 0.883 
    Safety consciousness 12 (10, 0–18) 8 (7, 3–14) 0.352 
    Fearfulness 28 (10, 12–35) 16 (7, 8–36) 0.405 
    Social interaction 13.5 (10, 2–22) 17 (7, 8–25) 0.282 
    Eye contact 3 (10, 0–8) 6 (7, 0–10) 0.258 
    Emotional engagement 7.5 (10, 4–14) 6 (7, 2–13) 0.257 
    Comfort seeking 10 (10, 8–14) 11 (7, 0–20) 0.428 
    Attention 12 (10, 6–18) 11 (7, 3–18) 0.883 
    Self-control/compliance 6 (10, 0–16) 10 (7, 4–18) 0.281 
    Mood, anger and aggression 5.5 (10, 0–42) 19 (7, 2–33) 0.117 
    Self-gratification 0 (10, 0–2) 2 (7, 0–5) 0.217 
Discussion 
In the 2–9-year age range, gross motor skills were the only adaptive skills that differentiated 
between the MPS III and ID groups. In the 10–15-year age group, the ID group showed 
significantly more advanced adaptive skills than the MPS III group in all areas of daily living 
skills, written communication and coping skills and in current understanding and current 
expression. Thus, level of disability increased with age in the MPS III group, while the ID 
group acquired new skills with age, possibly accounting for the age-related decrease in 
challenging behaviour in MPS III as they lose physical and cognitive skills and are less able 
to actually perform such behaviour. Although such behavioural problems are a feature of the 
middle phase of MPS III, the high frequency is not in itself phenotypic and may be associated 
with ID level. Middle phase children with MPS III displayed significantly more behaviours 
relating to hyperactivity, orality, body movements, interactions with objects and inattention 
than the control group, but given the poor internal consistency of the interactions with objects 
domain on the SBRS, this finding should be viewed with caution. Such behaviours may be 
part of the behavioural phenotype of the middle phase of MPS III, but this requires further 
investigation [36,37]. In the late phase MPS III group, few behaviours remained problematic; 
possibly, parents were used to managing higher levels of challenging behaviour in the middle 
phase and/or because the reduction in challenging behaviour corresponded to the inevitable 
physical and cognitive deterioration—one parent remarked that they wished their child was 
still able to display challenging behaviour. 
The present findings confirm previous reports of behaviours relating to orality, unusual affect 
and hyperactivity in the middle phase of MPS III and add that they occur significantly more 
frequently compared to matched controls. A novel finding was of unusual body movements 
being phenotypic in the middle stage of MPS III. The previously reported high rates of 
challenging behaviour and physical aggression in MPS III were found to be no different from 
matched controls in the middle phase and are probably associated with the level of ID. 
Interestingly, although unusual/inappropriate affect were no more frequent compared to 
matched controls, they were displayed by children with MPS III throughout their lives and 
even after other behaviours had disappeared. Unlike previous research, this study did not 
examine ‘temper tantrums’ as these are poorly defined and subjective in report. This study 
found sleep disturbance to be a common problem in MPS III but with lower prevalence than 
previous studies, which with a parallel of sleep in MPS III that identified that the quantity of 
night-time sleep in children with MPS III was not significantly different from typically 
developing children [23]. 
This study was limited by the small sample size and grouping of MPS III subtypes. It is 
possible that the within-group variability found in this study could be accounted for by 
genetic subtype. As MPS III subtypes are genetically distinct, the findings of this study can 
only be described as preliminary and identify areas to focus future research. A larger sample 
size would also show fewer outliers, as was the case in the late phase MPS III sample where 
there was an outlier in terms of ability, although this did not substantially affect the findings, 
and it is likely that this was a case of the MPS III B mild phenotype and thus indicative of the 
heterogeneous presentation of MPS III [15,14]. 
The SBRS is a relatively under-developed measure that requires further work to improve its 
psychometric properties, and therefore, the data derived from the SBRS should be treated 
with caution. 
Clinical implications 
The present findings indicate that families with children with MPS III may benefit from a 
different type of support service, in addition to their medical treatment, in the middle phase 
compared to the late phase of the disorder. In the middle phase, needs associated with 
hyperactivity and behavioural concerns could be met by community learning disability 
services, while issues relating to deterioration and loss of skills and end-of-life care in the late 
phase may be best met by paediatric psychology services, although the heterogeneity in 
individual presentation means the age at which these needs change will vary. In the middle 
phase, the behavioural problems related to inattention and hyperactivity may benefit from the 
same type of behavioural interventions as children of a similar developmental level diagnosed 
with Attention Deficit Hyperactivity Disorder (ADHD). Additionally, a parallel study found 
that parents of children with MPS III experience similar levels of stress to those with a child 
with ID [23]. The National Institute for Clinical Excellence (NICE) guidelines recommend 
parenting groups as the primary intervention for children with ADHD and ID with 
subsequent individual parenting skills interventions if necessary [38]. As behavioural 
interventions are effective in MPS III [5], parenting interventions could be developed for 
parents of children with MPS III which could address both managing behavioural issues and 
coping with the progressive, terminal prognosis of MPS III. 
Conclusions 
Although this study was predicated on a biological basis for the behaviour of children with 
MPS III, the complex relationship between environment, biology, learning and personal 
factors must be considered given that social context [39], physical environment and triggers 
[40] and effect of personal characteristics on phenotypic behaviour [41] are demonstrably 
important when examining behaviour in other genetic syndromes. Examination of differences 
in behavioural presentation between the genetic subtypes of MPS III would also inform the 
understanding of the genotype-phenotype relationship in MPS III, but this may be difficult 
within a UK sample and might require international recruitment, possibly utilising on-line 
data collection. 
No single questionnaire in this study captured the behavioural phenotype or was completed 
by parents exactly according to guidelines, and the present findings should inform further 
development of existing and novel questionnaire-based measures for use with this small but 
important population [9,10]. Moreover, given the progressive nature of MPS III coupled with 
the evident phenotypic heterogeneity, future research could use more naturalistic 
methodologies with an emphasis on describing the progressive nature of the disorder rather 
than on mapping evident differences. 
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